Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and sb 202190

sorafenib has been researched along with sb 202190 in 10 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(sb 202190)		Trials
(sb 202190)		Recent Studies (post-2010) (sb 202190)
6,5207305,2516510202

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)sb 202190 (IC50)
Mitogen-activated protein kinase 13Homo sapiens (human)0.08
Bromodomain-containing protein 4Homo sapiens (human)2.95
TyrosinaseMus musculus (house mouse)0.03
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)0.08
Casein kinase I isoform deltaHomo sapiens (human)0.188
Mitogen-activated protein kinase 12Homo sapiens (human)0.08
Mitogen-activated protein kinase 11Homo sapiens (human)0.1038
Mitogen-activated protein kinase 14Homo sapiens (human)0.0625
Tau-tubulin kinase 2Homo sapiens (human)9.34
large T antigenBetapolyomavirus macacae4.87

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Hah, JM; Kim, H; Kim, M; Lee, J; Yu, H1
Chen, Y; Chen, YZ; Chu, B; Gao, D; Jiang, Y; Jin, F; Liu, F; Tan, C; Zhang, C1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aman, W; Hah, JM; Jung, K; Kim, H; Kim, M; Lee, J; Ryu, JS1
Del Rio, A; Grossi, V; Ingravallo, G; Liuzzi, M; Martelli, N; Murzilli, S; Napoli, A; Simone, C1

Other Studies

10 other study(ies) available for sorafenib and sb 202190

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.
    Bioorganic & medicinal chemistry, 2011, Nov-15, Volume: 19, Issue:22

    Topics: Amides; Azepines; Cell Growth Processes; Cell Line, Tumor; Humans; Melanoma; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Pyrazoles; Structure-Activity Relationship; U937 Cells

2011
Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
    Bioorganic & medicinal chemistry, 2013, Feb-01, Volume: 21, Issue:3

    Topics: Antineoplastic Agents; Benzopyrans; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Mitogen-Activated Protein Kinase 8; Models, Molecular; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Structure-Activity Relationship

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Structure-Activity Relationship; U937 Cells

2014
Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transplantation, Heterologous

2012